sunitinib (Sutent)

Advice

following a full submission

sunitinib (Sutent®) is accepted for use within NHS Scotland.

Indication under review: Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults.

Treatment with sunitinib improved progression free survival compared with placebo in patients with well-differentiated neuroendocrine carcinoma of the pancreas who were receiving best supportive care, including somatostatin analogues if required for symptomatic control.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of sunitinib. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland.